Look back at pharma news to Sept 23

25 September 2016
mergers-acquisitions-big

By Barbara Obstoj-Cardwell. Editor

Cash-rich since its $40.5 billion sale of its generics business to Teva Pharmaceutical Industries, Ireland -incorporated Allergan was on the takeover trial again last week, announcing two acquisitions, -  Arkana Therapeutics and Tobira Therapeutics - making its total buys in the year to date seven.

Once again, Allergan proved that there’s no premium too big when it has identified a company it wants to purchase, according to Ben Levisohn in an article for Barron’s magazine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical